Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus

Abstract

Objective

We aimed to assess the impact of introducing immunoprophylaxis against respiratory syncytial virus in infants (healthy infants up to 6 months of age and vulnerable children up to 24 months) on the professional quality of life of pediatric healthcare providers, and to analyze its association with factors such as sex, age, work experience, workplace setting, professional role, and involvement in pediatric emergency departments.

Methods

We conducted an observational, analytical, cross-sectional, multicenter study in Valencia and Castellon Health Departments. The Professional Quality of Life Scale (ProQOL-21) was used to assess compassion satisfaction, burnout, and secondary traumatic stress, the latter two being components of compassion fatigue. Data were collected during two bronchiolitis periods: 2022–2023 (pre-Nirsevimab) and 2023–2024 (post-Nirsevimab). These three dimensions were analyzed across both periods and in relation to demographic and professional variables.

Results

A total of 213 surveys were collected (113 pre-Nirsevimab and 100 post-Nirsevimab). The results revealed a significant decrease in burnout and secondary traumatic stress, along with an increase in compassion satisfaction. Improvements were particularly notable among professionals working in emergency departments, hospitals, those under 35 years of age, women, and those with less than 10 years of work experience. No significant improvements were observed in men or residents across any of the dimensions.

Implications for practice

The implementation of immunoprophylaxis against respiratory syncytial virus has not only improved patient outcomes but has also positively impacted the emotional well-being of pediatric healthcare providers, highlighting the importance of implementing preventive strategies to support healthcare professionals.